Market open
Instil Bio/$TIL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Instil Bio
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Ticker
$TIL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
49
Website
Instil Bio Metrics
BasicAdvanced
$185M
Market cap
-
P/E ratio
-$18.39
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$185M
Beta
1.19
52-week high
$67.36
52-week low
$6.07
Average daily volume
156K
Financial strength
Current ratio
15.057
Quick ratio
14.459
Long term debt to equity
43.045
Total debt to equity
43.901
Interest coverage (TTM)
-8.79%
Management effectiveness
Return on assets (TTM)
-12.45%
Return on equity (TTM)
-48.65%
Valuation
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-3.188
Growth
Earnings per share change (TTM)
-35.70%
3-year earnings per share growth (CAGR)
-17.97%
What the Analysts think about Instil Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Instil Bio stock.
Instil Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Instil Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Instil Bio News
AllArticlesVideos
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
GlobeNewsWire·2 months ago
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Seeking Alpha·2 months ago
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Instil Bio stock?
Instil Bio (TIL) has a market cap of $185M as of November 08, 2024.
What is the P/E ratio for Instil Bio stock?
The price to earnings (P/E) ratio for Instil Bio (TIL) stock is 0 as of November 08, 2024.
Does Instil Bio stock pay dividends?
No, Instil Bio (TIL) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Instil Bio dividend payment date?
Instil Bio (TIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Instil Bio?
Instil Bio (TIL) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.